Quick Takeaways
- Trails Edge Capital Partners, LP filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 6.1%.
- Date of event: 31 Mar 2026.
Quoteable Key Fact
"Trails Edge Capital Partners, LP disclosed 6.1% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT) on 31 Mar 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Trails Edge Capital Partners, LP | 6.1% | 8,057,345 | 8,057,345 | 0 | Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC | |
| Trails Edge Biotechnology Master Fund, LP | 6.1% | 8,057,345 | 8,057,345 | 0 | Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC | |
| Ortav Yehudai | 6.1% | 8,057,345 | 8,057,345 | 0 | /s/ Ortav Yehudai | Ortav Yehudai / Individual |